Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05410418
Title Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

follicular lymphoma

Therapies

Mosunetuzumab + Polatuzumab vedotin-piiq

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.